VistaGen Therapeutics Reports Phase 3 Fasedienol Trial Fails to Meet Primary Endpoint in Social Anxiety Disorder
I'm PortAI, I can summarize articles.
VistaGen Therapeutics announced that its Phase 3 PALISADE-3 trial for intranasal fasedienol in treating social anxiety disorder failed to meet its primary endpoint. The trial showed no significant difference between fasedienol and placebo. The safety profile was consistent with previous studies. Results were presented, and the information was published via EDGAR by VistaGen Therapeutics.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments